NKB2 주식 개요 상업화 단계의 바이오 제약 회사인 TG 테라퓨틱스는 미국 및 전 세계에서 B세포 매개 질환에 대한 새로운 치료제를 확보, 개발 및 상업화하는 데 주력하고 있습니다. 자세한 내용
{"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
생각, 링크 및 회사 내러티브를 캡처하세요.
TG Therapeutics, Inc. 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 TG Therapeutics 과거 주가 현재 주가 US$29.55 52주 최고치 US$34.17 52주 최저치 US$12.08 베타 2.26 1개월 변경 6.24% 3개월 변경 사항 -2.57% 1년 변경 사항 129.60% 3년 변화 200.79% 5년 변화 100.20% IPO 이후 변화 817.13%
최근 뉴스 및 업데이트 TG Therapeutics, Inc. Provides Revenue Guidance for Fourth Quarter, Full Year of 2024 and Full Year 2025 Jan 15
CFO, Corporate Secretary & Treasurer recently sold €606k worth of stock Jan 09
Insufficient new directors Dec 30
Independent Director recently sold €448k worth of stock Nov 09
Third quarter 2024 earnings released: EPS: US$0.027 (vs US$0.80 in 3Q 2023) Nov 04
TG Therapeutics, Inc. to Report Q3, 2024 Results on Nov 04, 2024 Nov 01 더 많은 업데이트 보기 TG Therapeutics, Inc. Provides Revenue Guidance for Fourth Quarter, Full Year of 2024 and Full Year 2025 Jan 15
CFO, Corporate Secretary & Treasurer recently sold €606k worth of stock Jan 09
Insufficient new directors Dec 30
Independent Director recently sold €448k worth of stock Nov 09
Third quarter 2024 earnings released: EPS: US$0.027 (vs US$0.80 in 3Q 2023) Nov 04
TG Therapeutics, Inc. to Report Q3, 2024 Results on Nov 04, 2024 Nov 01
TG Therapeutics, Inc. Announces Updated Data Presentations Including New Five-Year Data from ULTIMATE I & II Phase 3 Trials Evaluating BRIUMVI (Ublituximab-Xiiy) in Patients with Relapsing Forms of Multiple Sclerosis Sep 18
Investor sentiment improves as stock rises 18% Aug 23
TG Therapeutics Receives U.S. Food and Drug Administration Clearance for Its Investigational New Drug (IND) Application Aug 09
Second quarter 2024 earnings released: EPS: US$0.048 (vs US$0.34 loss in 2Q 2023) Aug 07
Investor sentiment deteriorates as stock falls 17% Aug 05
TG Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Aug 05
Independent Director recently sold €404k worth of stock Jun 21
Los Angeles County Employees Retirement Association Files an Exempt Solicitation Statement with Securities and Exchange Commission Jun 14
CalSTRS Files an Exempt Solicitation Statement to Shareholders of TG Therapeutics Jun 13
Investor sentiment improves as stock rises 30% May 08
First quarter 2024 earnings released: US$0.073 loss per share (vs US$0.28 loss in 1Q 2023) May 02 TG Therapeutics, Inc. to Report Q1, 2024 Results on May 01, 2024
Lead Independent Director recently sold €322k worth of stock Mar 14
Full year 2023 earnings released: EPS: US$0.089 (vs US$1.47 loss in FY 2022) Feb 29
TG Therapeutics, Inc. to Report Q4, 2023 Results on Feb 27, 2024 Feb 05
Forecast breakeven date pushed back to 2024 Jan 12
CFO, Corporate Secretary & Treasurer recently sold €742k worth of stock Jan 08
Third quarter 2023 earnings released: EPS: US$0.80 (vs US$0.27 loss in 3Q 2022) Nov 03
TG Therapeutics, Inc. to Report Q3, 2023 Results on Nov 01, 2023 Oct 31
Forecast breakeven date pushed back to 2025 Oct 13
Chairman recently bought €924k worth of stock Aug 15
Second quarter 2023 earnings released: US$0.34 loss per share (vs US$0.30 loss in 2Q 2022) Aug 02
TG Therapeutics, Inc. to Report Q2, 2023 Results on Aug 01, 2023 Aug 01
Independent Director recently sold €748k worth of stock Jun 27
Forecast breakeven date moved forward to 2024 Jun 26
CFO, Corporate Secretary & Treasurer recently sold €1.8m worth of stock Jun 06
Tg Therapeutics Announces European Commission Approval for Briumvi (Ublituximab-Xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults Jun 03
Tg Therapeutics Announces European Commission Approval for Briumvi (Ublituximab-Xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults Jun 02
First quarter 2023 earnings released: US$0.28 loss per share (vs US$0.51 loss in 1Q 2022) May 02
Insufficient new directors May 01
No longer forecast to breakeven Mar 03
Full year 2022 earnings released: US$1.47 loss per share (vs US$2.63 loss in FY 2021) Mar 01
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab) in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum Feb 15
TG Therapeutics Announces Commercial Launch of BRIUMVI™ (ublituximab-xiiy) for the Treatment of Adult Patients with Relapsing Forms of Multiple Sclerosis Jan 28
Lead Independent Director recently sold €314k worth of stock Jan 08
Forecast to breakeven in 2025 Dec 31
TG Therapeutics, Inc. Announces FDA Approval of BRIUMVI™ (ublituximab-xiiy) Dec 29
TG Therapeutics, Inc. to Report Q3, 2022 Results on Nov 10, 2022 Nov 09
Hagens Berman, National Trial Attorneys, Encourages TG Therapeutics Investors with Losses to Contact Firm’S Attorneys Before Sept. 16Th Deadline in Securities Fraud Class Action Sep 07
TG Therapeutics, Inc. Announces Results from the ULTIMATE I & II Phase 3 Trials of Investigational Ublituximab in RMS Aug 26
Second quarter 2022 earnings released: US$0.29 loss per share (vs US$0.59 loss in 2Q 2021) Aug 09
Pomerantz Law Firm Announces the Filing of A Class Action Against TG Therapeutics, Inc Jul 19
TG Therapeutics Announces FDA Extension of BLA PDUFA Date for Ublituximab to Treat Patients with RMS Jun 01
First quarter 2022 earnings released: US$0.51 loss per share (vs US$0.69 loss in 1Q 2021) May 11
TG Therapeutics, Inc., Annual General Meeting, Jun 16, 2022 May 02
TG Therapeutics, Inc. Announces Voluntary Withdrawal of the BLA/sNDA for U2 to Treat Patients with CLL and SLL Apr 16
TG Therapeutics, Inc. Announces Data Presentations from the Ultimate I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented At the American Academy of Neurology Annual Meeting Apr 05
TG Therapeutics Announces Extension of U.S. FDA BLA/sNDA PDUFA Date for Ublituximab Plus UKONIQ® (U2) to Treat Patients with CLL and SLL Mar 06
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Mar 02
TG Therapeutics, Inc. Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum Feb 26
TG Therapeutics, Inc. to Report Q4, 2021 Results on Mar 01, 2022 Feb 25 TG Therapeutics, Inc. Announces Data from the UNITY-CLL Phase 3 Trial Presented At the 63rd American Society of Hematology Annual Meeting
Third quarter 2021 earnings released: US$0.65 loss per share (vs US$0.73 loss in 3Q 2020) Nov 06
TG Therapeutics Announces Publication of Results from an Integrated Safety Analysis of UKONIQ® (umbralisib) in Blood Advances Sep 24
TG Therapeutics, Inc. Announces Combination Data Presentations at the XIX International Workshop on Chronic Lymphocytic Leukemia Sep 21
Second quarter 2021 earnings released: US$0.59 loss per share (vs US$0.47 loss in 2Q 2020) Aug 03
No longer forecast to breakeven Aug 03 TG Therapeutics, Inc.(NasdaqCM:TGTX) dropped from Russell 3000E Value Index
TG Therapeutics, Inc. Announces Presentation of Data from the Ultimate I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis At 7th Congress of the European Academy of Neurology Jun 19
TG Therapeutics, Inc. Announces Data from Phase 1 Study Evaluating TG-1701 as a Monotherapy Jun 05
TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab in Combination with UKONIQ® (umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma May 26
First quarter 2021 earnings released: US$0.69 loss per share (vs US$0.48 loss in 1Q 2020) May 11
TG Therapeutics Announces Publication of Results from the UNITY-NHL Phase 2B Trial Evaluating Umbralisib Mar 10
TG Therapeutics, Inc. to Present Results from the ULTIMATE I & II Phase 3 Trials Evaluating Ublituximab in Multiple Sclerosis at the American Academy of Neurology 73rd Annual Meeting Mar 05
Revenue misses expectations Mar 02
Full year 2020 earnings released: US$2.42 loss per share (vs US$1.96 loss in FY 2019) Mar 02
TG Therapeutics, Inc. to Report Q4, 2020 Results on Mar 02, 2021 Feb 27
TG Therapeutics Announces Publication of Final Results from the Phase 3 Genuine Trial Evaluating Ublituximab Plus Ibrutinib in Patients with Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia in the Lancet Haematology Feb 24
TG Therapeutics, Inc. Announces FDA Accelerated Approval of UKONIQ™ (Umbralisib) Feb 06
New 90-day high: €45.80 Jan 14
TG Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $274.92 million. Dec 15
Independent Director recently sold €992k worth of stock Dec 12
TG Therapeutics Announces Positive Topline Results from the ULTIMATE I & II Phase 3 Studies Evaluating Ublituximab Monotherapy for the Treatment of Patients with Multiple Sclerosis Dec 12
New 90-day high: €33.34 Dec 11
TG Therapeutics Announces Publication of Phase 2 Data Evaluating Umbralisib in Patients with Chronic Lymphocytic Leukemia Who Are Intolerant to Prior BTK or PI3K Inhibitor Therapy in Blood Dec 03
TG Therapeutics Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration for Approval of Ublituximab Investigational Glycoengineered Anti-CD20 Monoclonal Antibody Dec 02
Revenue beats expectations Nov 11
Third quarter 2020 earnings released: US$0.73 loss per share Nov 11
New 90-day high: €23.30 Oct 01
New 90-day high - €21.29 Sep 02
First half earnings released Aug 10
TG Therapeutics, Inc. to Report Q2, 2020 Results on Aug 10, 2020 Aug 07
TG Therapeutics, Inc.(NasdaqCM:TGTX) dropped from Russell Microcap Growth Index Jul 04
TG Therapeutics, Inc.(NasdaqCM:TGTX) dropped from Russell Microcap Value Index Jul 02 주주 수익률 NKB2 DE Biotechs DE 마켓 7D -4.9% 1.2% 2.3% 1Y 129.6% -5.6% 16.7%
전체 주주 수익률 보기
수익률 대 산업: NKB2 지난 1년 동안 -5.6 %를 반환한 German Biotechs 산업을 초과했습니다.
수익률 대 시장: NKB2 지난 1년 동안 16.7 %를 반환한 German 시장을 초과했습니다.
가격 변동성 Is NKB2's price volatile compared to industry and market? NKB2 volatility NKB2 Average Weekly Movement 9.7% Biotechs Industry Average Movement 5.7% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.5%
안정적인 주가: NKB2 의 주가는 지난 3개월 동안 German 시장과 비교해 변동성이 컸습니다.
시간에 따른 변동성: NKB2 의 주간 변동성 ( 10% )은 지난 1년 동안 안정적이었지만 여전히 German 의 75%보다 높습니다. 주식.
회사 소개 상업화 단계의 바이오 제약 회사인 TG 테라퓨틱스는 미국 및 전 세계에서 B세포 매개 질환에 대한 새로운 치료제를 인수, 개발 및 상업화하는 데 주력하고 있습니다. 이 회사는 임상적으로 고립된 증후군, 재발 완화 질환 및 성인 활동성 이차 진행성 질환을 포함한 재발성 다발성 경화증(RMS) 성인 환자 치료를 위한 항-CD20 단일클론 항체 브룸비(BRIUMVI)를 제공합니다. 회사의 개발 파이프라인은 재발성 또는 불응성 변연부 림프종 및 여포성 림프종 성인 환자 치료를 위한 경구용 PI3K-델타 억제제인 움브랄리시브(Umbralisib), 시험관 내 키나제 스크리닝에서 BTK에 선택성을 보이는 경구용 공유 결합 브루톤 티로신 키나제(BTK) 억제제인 TG-1701, 이중 특이적 CD47 및 CD19 항체인 TG-1801 등으로 구성돼 있습니다.
자세히 보기 TG Therapeutics, Inc. 기본 사항 요약 TG Therapeutics 의 수익과 매출은 시가총액과 어떻게 비교하나요? NKB2 기본 통계 시가총액 €4.30b 수익(TTM ) -€13.82m 수익(TTM ) €254.75m
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) NKB2 손익 계산서(TTM ) 수익 US$264.79m 수익 비용 US$30.94m 총 이익 US$233.85m 기타 비용 US$248.21m 수익 -US$14.36m
주당 순이익(EPS) -0.10 총 마진 88.31% 순이익 마진 -5.42% 부채/자본 비율 127.1%
NKB2 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2025/02/12 01:03 장 마감 주가 2025/02/12 00:00 수익 2024/09/30 연간 수익 2023/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기 .
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.
애널리스트 출처 TG Therapeutics, Inc. 20 애널리스트 중 6 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Alec Stranahan BofA Global Research Jonathan Aschoff Brean Capital Mayank Mamtani B. Riley Securities, Inc.
17 더 많은 분석가 보기 
